Acarix

Acarix FCF Margin

The Free Cash Flow Margin of Acarix (ACARIX.ST) as of Nov 12, 2026 is -667.57 %. In the previous year, Free Cash Flow Margin was -1,035.88 % — a change of -35.55% (higher).

FCF Margin

-667.57 %

YoY

-35.55%

Last updated:

Free Cash Flow Margin of Acarix is 2025 -667.57 % . Free Cash Flow Margin of Acarix was 2024 -1,035.88 % . It decreases by -35.55% higher compared to the previous year.

The Acarix FCF Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Margin
Date
FCF Margin
Jan 1, 2018
-3,774.61 SEK
Jan 1, 2019
-2,400.43 SEK
Jan 1, 2020
-1,692.58 SEK
Jan 1, 2021
-1,277.93 SEK
Jan 1, 2022
-1,288.56 SEK
Jan 1, 2023
-1,304.09 SEK
Jan 1, 2024
-1,035.88 SEK
Jan 1, 2025
-667.57 SEK
The Acarix FCF Margin history
YEARFCF MarginYoY
-667.57 %-35.55%
-1,035.88 %-20.57%
-1,304.09 %+1.20%
-1,288.56 %+0.83%
-1,277.93 %-24.50%
-1,692.58 %-29.49%
-2,400.43 %-36.41%
-3,774.61 %-44.67%
-6,821.79 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Acarix Stock analysis

What does Acarix do? Acarix AB generates revenue through the sale of its primary medical device, the CADScor System, which utilizes phonocardiography for coronary artery disease monitoring. The system is designed for use by physicians, nurses, and laboratory technicians in clinical settings, featuring a chest patch with a recording head positioned at the fourth left intercostal space and a sensor on the sternum. Patients undergo a two-minute heart sound recording guided by audio cues and display instructions, after which the CAD-score is calculated and displayed for diagnostic purposes. The company's business model relies on direct sales of the CADScor System to healthcare providers, including hospitals and diagnostic laboratories, where the device is used for non-invasive rule-out diagnosis of coronary artery disease. The system's unique phonocardiography technique and algorithm-based scoring provide a streamlined diagnostic process, reducing the need for more invasive procedures and appealing to medical professionals seeking efficient diagnostic tools. Acarix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acarix stock

Free Cash Flow Margin of Acarix is -667.57 % in 2025.

Free Cash Flow Margin of Acarix changed from -1,035.88 % to -667.57 %, representing a -35.55% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Margin Acarix since 2006 – with annual values, charts, and detailed analysis.

FCF Margin measures the percentage of revenue converted to free cash flow. It indicates how efficiently a company generates cash from its operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Margin's Acarix with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Acarix

All Key Metrics — Acarix